The Food and Drug Administration FDA or Agency is announcing the publication of a draft Strategy Document for public comment outlining specific actions FDA will take during fiscal years 2023-2027 to facilitate the use of innovative manufacturing technologies. As part of the Prescription Drug User Fee Act PDUFA Reauthorization Performance Goals and Procedures Fiscal Years 2023-2027 PDUFA VII FDA committed to advance the use and implementation of innovative manufacturing. In connection with this effort on June 8 2023 FDA participated in a public workshop on the use of innovative manufacturing technologies for products regulated by the Center for Drug Evaluation and Research CDER and the Center for Biologics Evaluation and Research CBER including barriers to their adoption. FDA also committed to issuing this draft Strategy Document for public comment. The actions described in the draft Strategy Document are based on lessons learned from FDA's experiences with submissions involving advanced manufacturing technologies as well as feedback from the workshop and other public input.